NanoString will utilize IP from a 20-gene expression assay developed by the Lymphoma/Leukemia Molecular Profiling Project (LLMP) to develop a companion diagnostic test to support clinical validation of Celgene’s REVLIMID®. NanoString could receive up to $45 million in payments under the deal.
NanoString Inks $45 million CDx Collaboration With Celgene
Jun 3, 2014 | News